Chinese biotech Innovent Biologics (HKEX: 01801) has secured approval from China’s National Medical Products Administration ...
The FDA granted full approval encorafenib (Braftovi) in combination with cetuximab (Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...
BeOne Medicines Q4 earnings and revenue beat the Street's expectations; the outlook missed by a small margin. Read why I have ...
The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.
AstraZeneca (LSE:AZN) received US FDA approval for CALQUENCE as an all oral, fixed duration therapy for chronic lymphocytic ...
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today key clinical ...
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune ...
A newly approved combination of acalabrutinib plus venetoclax gives with newly diagnosed chronic lymphocytic leukemia (CLL) another chemotherapy-free option that is taken for a fixed period of time ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ('Ascentage Pharma” or the 'Company”), a global, commercial ...
AstraZeneca has secured approval in the US for Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with chronic lymphocytic leu ...
AbbVie announces US FDA approves combination treatment of Venclexta and acalabrutinib for previously untreated patients with CLL: North Chicago, Illinois Monday, February 23, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results